Medix Biochemica acquires CANDOR Bioscience
Medix Biochemica expands its offering of critical in vitro diagnostics (IVD) raw materials to premium blockers and stabilizers by acquiring CANDOR Bioscience.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 542 entries already.
Entries by Michael Kuhrt
2024 BioFIT, MedFIT and MEDigIT editions: Fostering innovation and excellence in the healthcare sector
Lille hosted the 2024 editions of BioFIT, MedFIT, and MEDigIT, three internationally recognised events dedicated to innovation in Life Sciences, MedTech and Digital Health. These gatherings serve as catalysts for collaboration and progress, each focusing on a specific aspect of the healthcare innovation landscape.
InflaRx secures European Commission approval for ARDS drug
Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
Synairgen raises £18m for Phase 2 INVENT trial of SNG001
Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 billion deal involves J&J paying $132 per share, representing a 39% premium over Intra-Cellular’s last closing price.
Leyden Labs secures $70M to advance intranasal antibody therapies
Leyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses.
First in vivo CAR gene therapy trial in Europe approved
The Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell malignancies.
Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders
Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
New RNA company Inverna Therapeutics launched
Inverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and Argobio, Inverna will focus on its lead programme addressing Huntington’s disease.
Jeito Capital leads $67.5m Series B financing for cardiovascular gene therapy
A US$67.5m Series B financing in XyloCor Therapeutics led by French Jeito Capital will fund two double-blind Phase 2 trials for XC001, a pioneering gene therapy for severe cardiovascular disease.